KalaGhazii

KalaGhazii

Netflix's Ad Business Is a Huge Hit: Time to Buy the Stock?

KalaGhazii

They're buying Seagen for $43 billion so they can build an anti-cancer franchise. They need this. Pfizer has a strong pipeline, but when will they get behind their migraine drug, which was part of an acquisition? They're doing nothing with it.

KalaGhazii

Corvus Pharmaceuticals Extends Gains in Premarket Thursday After Reporting 'Strong Progress' in Immune Diseases Treatment On Wednesday, the company said it will present new data for CPI-818 at the International Conference on Malignant Lymphoma meeting in Lugano, Switzerland from June 13 to 17.

KalaGhazii

Oil is still trading on bearish. We might see target 74 - 76 tomorrow?

KalaGhazii

75 COULD BE OUR NEXT TARGET ? What you guys think about hitting 75 We are still in the bear market

KalaGhazii

Nio stock has been doing really well until covid Buy zone 6 to 5

KalaGhazii

Rise and shine! Meta Platform has been performing really well in the past few months

KalaGhazii

Oil is still in the bear zone My prediction today 70.00 then 75.00???

KalaGhazii

Will history repeat itself EUR/USD looking bearish Target 10.5

KalaGhazii

60 could be our magic number. We are still in the bearish market. The rectangle could be the rejection zone!

KalaGhazii

Gold still around the 2000s We might see gold to 1950

KalaGhazii

we might see some noise next week as people holding buy from 65 Looks like we are still in the bearish trend

KalaGhazii

A lot of decline in April We might see a comeback this month! 70 -75 range

KalaGhazii

@KalaGhazi Esperion Therapeutics Big drop yesterday. Will it rally or back down again???

KalaGhazii

@KalaGhazi #CARVANA CO looks like its going for a heavy ride!

KalaGhazii

@KalaGhazi #ObsEva SA has been volatile last week I do see an upside Good luck

KalaGhazii

Hi everyone, this is KalaGhazi and today I will be talking about Reata that just rocketed 200% yesterday. Reata Pharmaceuticals RETA stock skyrocketed almost 200% on Wednesday, a day after the FDA approved its drug Skyclarys, or omaveloxolone, across a broad patient population of an ultra-rare disease called Friedreich’s ataxia. Shares of Reata have surged 200.3%...